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 Genetic and epigenetic inactivation of SESTRIN1
controls mTORC1 and response to EZH2 inhibition in
follicular lymphoma
Elisa Oricchio,1* Natalya Katanayeva,1 Maria Christine Donaldson,1 Stephanie Sungalee,1
Pasion P. Joyce,2 Wendy Béguelin,3 Elena Battistello,1,4 Viraj R. Sanghvi,2 Man Jiang,2
Yanwen Jiang,5 Matt Teater,5 Anita Parmigiani,6 Andrei V. Budanov,6,7 Fong Chun Chan,8,9
Sohrab P. Shah,10,11 Robert Kridel,8,12 Ari M. Melnick,3 Giovanni Ciriello,4 Hans-Guido Wendel2
Follicular lymphoma (FL) is an incurable form of B cell lymphoma. Genomic studies have cataloged common genetic
lesions in FL such as translocation t(14;18), frequent losses of chromosome 6q, andmutations in epigenetic regulators
such as EZH2. Using a focused genetic screen, we identified SESTRIN1 as a relevant target of the 6q deletion and dem-
onstrate tumor suppression by SESTRIN1 in vivo. Moreover, SESTRIN1 is a direct target of the lymphoma-specific EZH2
gain-of-function mutation (EZH2Y641X). SESTRIN1 inactivation disrupts p53-mediated control of mammalian target of
rapamycin complex 1 (mTORC1) and enables mRNA translation under genotoxic stress. SESTRIN1 loss represents an
alternative to RRAGC mutations that maintain mTORC1 activity under nutrient starvation. The antitumor efficacy of
pharmacological EZH2 inhibition depends on SESTRIN1, indicating thatmTORC1 control is a critical function of EZH2 in
lymphoma. Conversely, EZH2Y641Xmutant lymphomas show increased sensitivity to RapaLink-1, a bifunctional mTOR
inhibitor. Hence, SESTRIN1 contributes to the genetic and epigenetic control of mTORC1 in lymphoma and influences
responses to targeted therapies. http by guest on July 3, 2017
://stm
.sciencem
ag.org/INTRODUCTION
Genetic and epigenetic alterations in cancer point to the biological pro-
cesses driving tumor development and may reveal opportunities for
therapy (1). Follicular lymphoma (FL) is among the most common
forms of indolent B cell lymphoma, and cytogenetic studies have iden-
tified the chromosomal translocation t(14;18), which activates the anti-
apoptoticBCL2 gene, as a hallmark of the disease (2). Recent sequencing
studies have cataloged somatic mutations in FL. These include frequent
mutations in epigenetic regulators such as KMT2D, CREBBP, and
EZH2 (3–7), immune receptor genes such as TNFRSF14, CD79B, and
B2M (8–10), and somewhat less frequentmutations inmammalian tar-
get of rapamycin complex 1 (mTORC1) regulators such asRAGGC and
ATP6V1B2 (11).
FLs also harbor recurrent copy number changes, and the exact ge-
netic targets of large chromosomal lesions can be difficult to define. For
example, deletions of chromosome (Chr.) 6q occur in about 25 to 30%
of FLs, which have been linked to poor prognosis (12, 13). The tumor
suppressor genes A20/TNFAIP3 (14) and ephrin receptor A7 (EPHA7)(15) have been identified as targets of the Chr. 6q deletions. However,
the size and complexity of Chr. 6q lesions suggest the presence of ad-
ditional genetic targets. Unbiased genetic screens provide an efficient
way to pinpoint candidate tumor suppressor genes within large chro-
mosomal lesions (15, 16). Here, we identified the mTORC1 regulator
SESTRIN1 (17–20) as a tumor suppressor and treatment response
modifier in FL.RESULTS
SESTRIN1 is a functional target of Chr. 6q deletions in FL
Ameta-analysis of copynumber data from two large cohorts of indolent
FLs [Memorial Sloan Kettering Cancer Center (MSKCC), n = 64; Uni-
versity of Nebraska Medical Center (UNMC), n = 196] (GSE40989)
(21, 22) shows copy number losses at Chr. 6q in 34% (89 of 260) of the
analyzed cases (Fig. 1A and fig. S1A). GISTIC analysis (23) identifies
one peak on Chr. 6p21 and five significant [false discovery rate
(FDR) < 0.01] and frequently altered regions on Chr. 6q: Chr. 6q13,
Chr. 6q14, Chr. 6q16-21, Chr. 6q23, and Chr. 6q27 (Fig. 1B and table
S1). The frequency of homozygous andheterozygous deletions is similar
in the different regions, varying between 9 and 13% for the homozygous
and between 12 and 16% for the heterozygous (Fig. 1C and table S2).
Moreover, we identified individual samples harboring rare but highly
focal events (<5 Mb). These focal deletions are larger than commonly
described germline variants, and they are not listed in the database of
genomic variants (http://dgv.tcag.ca), indicating that they are tumor-
specific and may target functionally relevant genes associated with FL
development (table S3). For example, we identified focal losses targeting
TNFAIP3/A20 and SESTRIN1 (Fig. 1D), suggesting that SESTRIN1
may be a target of the Chr. 6q deletion in FL. However, despite this
focal alteration, most of the deletions targeting SESTRIN1 are large and
simultaneously also affect other genes including, for example, PRDM1.
To identify functionally relevant targets of the Chr. 6q deletions, we
performed unbiased RNA interference (RNAi) focused on genes1 of 10
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Fig. 1. Genomic analyses and a genetic screen identify SESTRIN1 as a functional target of Chr. 6q deletions in FL. (A) Integrative Genome View of Chr. 6q deletions
occurring in 34% (89 of 260) of FL tumors. (B) Analysis of recurrent deletions in Chr. 6 in FL using GISTIC algorithm. (C) Frequency of homozygous and heterozygous deletions
in Chr. 6q. (D) Integrative Genome View visualization of 10 of 260 cases with focal deletions (<5Mb) on Chr. 6q. Representative FL case with focal deletion affecting SESTRIN1 and
TNFAIP3 locus is shown in detail. (E) Flow cytometry validation of individual shRNAs linked togreen fluorescent protein (GFP) showingpercentages ofGFP-positive cells before and
after IL-3 withdrawal in pro–B cells transduced with the indicated constructs.Oricchio et al., Sci. Transl. Med. 9, eaak9969 (2017) 28 June 2017 2 of 10
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 encoded at Chr. 6q. We screened 81 genes [each gene was targeted
by one to six short hairpin RNAs (shRNAs)] for enhanced viability in
immortalized pro–B cells (FL5-12) that depend on interleukin-3 (IL-3)
(fig. S1B) (15, 24). FL5-12 pro–B cells represent a different phase of B
cell differentiation than B cells in FL tumors; however, they are a useful
in vitro model to screen for genetic modifiers that need to be further
explored in a relevant in vivo model of lymphomagenesis (25, 26). In
our screen, we identified 29 shRNAs enriched at least 1.5-fold, indicat-
ing a survival advantage in IL-3–depleted FL5-12 cells (table S4). As
expected, these included shRNAs against the tumor suppressor genes
Epha7 (15) andTnfaip3 (14). In addition, two of three shRNAs targeting
Sestrin1 scored positively in our screen, with fold change greater than
1.5 (P = 0.02) (fig. S1C).We confirmed their ability to significantly (P =
0.01) down-regulate Sestrin1 expression (fig. S1D), promote IL-3–
independent survival (Fig. 1E), and accelerate proliferation (fig. S1E).
Thus, Sestrin1 reduction enhances pro–B cell survival and indicates a
potential tumor suppressor function.
Deficiency of Sestrin1 promotes FL development in vivo
We used the vavBcl2 model of FL to directly test the effect of Sestrin1
deficiency on lymphoma development. Thismodel recapitulates key as-
pects of the genetics and pathology of human FL (15, 27). We trans-
duced vavBcl2 hematopoietic precursor cells (HPCs) with empty
vector MSCV-IRES-GFP or with the two shRNAs targeting Sestrin1
pinpointed by the screen, and we transplanted the modified vavBcl2
HPCs into lethally irradiated, syngeneic, wild-type animals (Fig. 2A).
In recipient mice, knockdown of Sestrin1 resulted in significant accel-
eration of lymphoma development (sh-1 Sestrin1: n = 10; median sur-
vival, 93 days; log-rank P= 0.041; sh-2 Sestrin1: n = 12; median survival,
82 days; log-rank P = 0.028) (Fig. 2B). The shRNAs selectively down-
regulated Sestrin1 expression and did not affect Sestrin2 or Sestrin3
(Fig. 2, C and D). Surface marker and pathological analyses confirmed
the similarity of control and Sestrin1-deficient murine lymphomas with
human FLs. For example, we found the pathognomonic follicular struc-
ture, lack of apoptosis by TUNEL (terminal deoxynucleotidyl transferase–
mediated deoxyuridine triphosphate nick end labeling), expression of
the germinal center (GC) markers peanut agglutinin (PNA) and BCL6,
somatic hypermutation in the VDJH4 variable region, and a predomi-
nant B220+ and CD19+ B cell population with modest infiltration of
CD4+ or CD8+ T cells in both controls and tumors expressing shRNAs
targeting Sestrin1 (Fig. 2E and fig. S2, A to C). Although the Ki67-
positive staining is low as in the human disease, loss of Sestrin1 sig-
nificantly increases tumor proliferation [average of the number of
Ki67-positive cells in control = 8.5%, sh-2 Sestrin1 = 23.1% (P = 0.02),
and sh1 Sestrin1 = 15.5% (P = 0.05)] (Fig. 2E and fig. S2D). Consistent
with Sestrin’s function as an upstream regulator ofmTORC1 (18–20), we
found increased phosphorylation of eukaryotic translation initiation
factor 4E–binding protein 1 (4EBP1) and ribosomal S6 protein by im-
munohistochemistry (Fig. 2F and fig. S2, E and F) and immunoblots of
Sestrin1-deficient lymphoma cells compared to the control (Fig. 2G).
Hence, Sestrin1 acts a tumor suppressor that controls mTORC1 activ-
ity in an animal model of FL.
SESTRIN1 is a direct target of repression by EZH2Y641X
in lymphoma
We examined the expression of SESTRIN1 in human B cells and in FL
and diffuse large B cell lymphoma (DLBCL) samples. SESTRIN1 ex-
pression is similar in naïve and memory B cells, centroblasts, centro-
cytes, FL, and DLBCL (fig. S3A) (GSE12195). By subdividing theOricchio et al., Sci. Transl. Med. 9, eaak9969 (2017) 28 June 2017tumor samples based on EZH2mutation status, we noticed a significant
reduction of SESTRIN1 expression in FL tumor samples that carried the
EZH2 gain-of-function mutation (EZH2Y641X; n = 5) compared to
samples that were EZH2 wild type (n = 52; P = 0.0038) (Fig. 3A). We
further observed the same significant association between SESTRIN1
expression and mutant EZH2Y641X in GC-type DLBCL (EZH2Y641X, n =
8; EZH2 wild type, n = 30; P = 0.022) (Fig. 3B and table S5) (28, 29).
Expression of SESTRIN2 and SESTRIN3 was not related to EZH2mu-
tation status in either FL or DLBCL samples (fig. S3, B to E). Chro-
matin immunoprecipitation–quantitative polymerase chain reaction
(ChIP-qPCR) using three separate probes covering the SESTRIN1
promoter revealed a significant (P ≤ 0.01) enrichment of EZH2 on
SESTRIN1 promoter (Fig. 3C and fig. S3F) associated with an increase
of H3K27me3 in EZH2Y641X mutated compared to EZH2 wild-type
cells in the same region (Fig. 3D and fig. S3G). Hence, expression of
SESTRIN1 is linked to the activity of the mutant EZH2Y641X polycomb
protein in lymphoma samples.
We directly tested the effect of EZH2 inhibition on SESTRIN1 gene
expression across a panel of cell lines. Gene expression data from lym-
phoma cell lines of EZH2wild type (n= 2) or EZH2Y641Xmutant (n= 6)
confirmed a significant loss of SESTRIN1 expression in EZH2Y641Xmu-
tant lines (FDR<0.01;P=8.86× 10−8) (Fig. 3E and table S6) (GSE40971)
comparable to the down-regulation observed in previously reported tar-
gets of EZH2 (fig. S3H) (30). Global level of H3K27me3 is higher in
EZH2Y641Xmutant than in theEZH2wild-type cells, and treatmentwith
the EZH2 inhibitor caused loss of the H3K27me3 mark (fig. S3I). This
change in the histone mark corresponded to a significant (P ≤ 0.01)
increase in SESTRIN1mRNA and protein expression in the EZH2Y641X
mutant cells (Fig. 3, E and F, and fig. S3J), whereas it had no effect on
SESTRIN1 expression in EZH2 wild-type lines (Fig. 3, F and G, and
table S7). To allay potential concerns about drug selectivity, we confirmed
that RNAi-mediated EZH2 knockdown in EZH2 mutant Karpas-422
cells caused induction of the SESTRIN1 mRNA (fig. S3K) (GSE41239),
and we obtained similar results using an additional EZH2 inhibitor,
EPZ-6438, in a panel of EZH2 wild-type and mutant lymphoma cells
(fig. S3L). ChIP demonstrated a significant (P < 0.05) GSK126-sensitive
associationof the SESTRIN1promoterwith theH3K27me3mark (Fig. 3H).
We performed ChIP-qPCR for the H3K27me3 mark and histone-3 in
EZH2Y641X mutant SU-DHL-6 cells treated with GSK126, showing an
association with the SESTRIN1 promoter but not the RPL30 or TNFAIP3
promoter used as controls (Fig. 3H and fig. S3M). An analysis of promoter
methylation and SESTRIN1 sequence in 15 primary FL samples and five
cell lines did not reveal aberrant CpG island methylation or mutations
(fig. S3N). Hence, the mutant polycomb factor EZH2Y641X controls
SESTRIN1 expression in lymphoma cells.
Next, we explored the genetic relationship between SESTRIN1 dele-
tions,mutation status ofEZH2, and recently reportedRAGCguanosine
triphosphatase (GTPase) (RRAGC) mutations that also act to increase
mTORC1 activity (11). The analysis of 172 FL samples revealed a sig-
nificant mutually exclusive relationship between alterations in EZH2,
RRAGC, and SESTRIN1 (P = 0.03), which affect 47% of the cases
(fig. S3O). Moreover, an analysis focused only on the relationship be-
tween SESTRIN1 loss and EZH2 mutations was performed across
multiple data sets, including 172 FL and 88 DLBCL (31, 32). Thirty-five
percent of the cases (92 of 260) harbor either EZH2 mutations or
SESTRIN1 loss, and only six cases show concurrent alteration of both
genes (P= 0.06) (fig. S3P). Together, these data indicate that SESTRIN1,
RRAGC, and EZH2 lesions are alternate events implicated inmTORC1
control in lymphoma.3 of 10
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 Mutant EZH2Y641X activates mTORC1 and mRNA translation
in lymphoma
SESTRIN family of proteins control mTORC1 activity in response to
p53 activation and reducemRNA translation in response toDNAdam-
age (17–19, 33). Therefore, we examined the cellular response to DNA
damage in the presence of the EZH2Y641X gain-of-function mutation.
We treated OCI-LY19 and SU-DHL-5 cells (wild type for p53 and
EZH2) and SU-DHL-10 and VAL cells (p53 wild type and EZH2Y641X)
(table S8) with the topoisomerase-2 inhibitor doxorubicin (DXR; 200 nM).
This treatment failed to induce SESTRIN1 expression in EZH2Y641X
mutant cells, whereas both EZH2 wild-type and mutant cell lines re-
sponded with induction of SESTRIN2 and p21 mRNAs (Fig. 4A and
fig.S4A). Consistently,DXRcaused an inhibitionofmTORC1 signaling,
as indicated by loss of phosphorylation of 4E-BP and ribosomal S6 in
wild-type cells but not in EZH2Y641Xmutant cells (Fig. 4B and fig. S4, B
and C; quantified in fig. S4, D and E). Hence, the EZH2Y641X gain-of-
function mutation can override mTORC1 inhibition caused by geno-
toxic stress in lymphoma cells by inhibiting SESTRIN1.
Next, we wondered whether the epigenetic control of mTORC1
strictly depends on SESTRIN1 orwhether there is a backupmechanism.
Treatment with the EZH2 inhibitor, GSK126, blocked mTORC1
signaling in EZH2Y641X mutant cells (SU-DHL-10, SU-DHL-6, and
Karpas-422) as indicated by loss of ribosomal S6 and 4E-BP phospho-
rylation (Fig. 4C and fig. S4F). By contrast, SESTRIN1 isogenic deficient
cells generated using clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas9 or shRNAs showed no effect on mTORC1 ac-
tivity (Fig. 4D and fig. S4, G and H). Moreover, metabolic labeling
of nascent protein production with a methionine synthetic analog
[L-azidohomoalanine (AHA)] revealed that SESTRIN1-proficient
lymphoma cells readily reduced translation rates by 23%, whereas
SESTRIN1-defective lymphoma cells were unable to reduce translation
in response to EZH2 inhibition; rapamycin was used as control, and, as
expected, it showed equal translation inhibition independent of
SESTRIN1 (Fig. 4, E and F). Hence, SESTRIN1 is an important node
that links EZH2 and the control of mTORC1 and mRNA translation.
Therapeutic EZH2 inhibition depends on SESTRIN1
The mutant EZH2Y641X protein can potentially control a large number
of genes, and it is not clear which of these are required for response to an
EZH2 inhibitor. We assessed the relative importance of SESTRIN1 by
treating isogenic SESTRIN1-competent and SESTRIN1-deficient lym-
phoma cells with GSK126. Treatment of EZH2Y641Xmutant SU-DHL-10
cells with GSK126 readily induced cell death in the parental line, whereas
SESTRIN1 inactivation in the same cells prevented cell death (fig. S4, I
and J). Next, we directly compared the in vivo response of isogenic pairs
of SESTRIN1-proficient (SU-DHL-10 vector) and SESTRIN1-deficient
(SU-DHL-10 CRISPR-Sestrin1) lymphomas to EZH2 inhibition.We xe-
nografted lymphomas into the right and left flanks of immunodeficient
(NOD.CB17-Prkdcscid) mice. We initiated treatment with EZH2 inhibi-
tor (GSK126) [75mg/kg intraperitoneally (ip) daily for 14days] or vehicle
once tumors had reached a size of 5 to 10 mm3. In SESTRIN1-proficient
tumors, GSK126 caused a significant (P = 0.013) growth reduction com-
pared to vehicle (Fig. 4G); in contrast, the SESTRIN1-deficient tumors
failed to respond to the EZH2 inhibitor (Fig. 4, H and I). Tumor analy-
ses by immunohistochemistry and immunoblots readily showed differ-
ential induction of apoptosis by cleaved caspase3 and differential
inhibition of mTORC1 activity by phosphorylation of ribosomal S6
and 4E-BP1 proteins between SESTRIN1-proficient and SESTRIN1-
deficient tumors (Fig. 4J and fig. S4, K and L). These results indicateOricchio et al., Sci. Transl. Med. 9, eaak9969 (2017) 28 June 2017that mutated EZH2 controls mTORC1 activity through SESTRIN1
in lymphoma.
We have seen that mutant EZH2 can override the p53-mediated in-
duction of SESTRIN1.Wenowwonderedwhether EZH2 inhibition and
SESTRIN1 expression also contribute to DNA damage response in-
duced by chemotherapeutic agents. We pretreated SU-DHL-10 lym-
phoma cells with the EZH2 inhibitor (GSK126, 2 mM) for 1 day, and
then we added DXR for an additional day (DXR, 50 nM). Pretreatment
with the EZH2 inhibitor reduced mTORC1 activity, as indicated by a
decrease in phospho-S6, but did not significantly enhance the antipro-
liferative effect of DXR in vitro (fig. S4, M and N).
EZH2 mutant lymphomas are sensitive to a bifunctional
mTOR inhibitor
EZH2mutant lymphoma cells showdown-regulation of SESTRIN1 and
mTORC1activation.Wewonderedwhether these tumorswere alsomore
sensitive to pharmacological mTORC1 inhibition. RapaLink-1 is a third-
generationmTORC1 inhibitor that binds both the FRB (FKBP-rapamycin
binding) and the mTORC kinase domains and therefore combines the
mTORC1 selectivity of rapamycinwith the better target inhibition ofmTOR
kinase inhibitors (Fig. 4K) (34). We treated a panel of EZH2 wild-type
(OCI-LY19, Toledo, and DoHH2) and EZH2 mutant (SU-DHL-10, SU-
DHL-4, andSU-DHL-6) lymphomacell lineswith low (12.5nM)andhigh
(50 nM)dose of RapaLink-1 for 48 hours.EZH2mutant cells weremore
sensitive to this inhibitor than EZH2 wild-type lines. Specifically, we ob-
servedcelldeath induction in80 to95%ofEZH2Y641Xmutantcells compared
to 10 to 70% of EZH2WT cells for both low and high drug concentrations
(Fig. 4L and fig. S4O). These results indicate specific pharmacological
vulnerabilities of EZH2Y641X mutant lymphomas.DISCUSSION
SESTRIN1 is a known regulator of mTORC1 that is transcriptionally
induced by p53 uponDNAdamage andmediates cell growth inhibition
upon genotoxic stress (17–19). Our study identifies the SESTRIN1 gene
as a bona fide tumor suppressor in lymphoma and a biologically rele-
vant target of the frequent Chr. 6q deletions that are observed in ~20%
of human lymphomas. These chromosomal deletions are typically large
and encompass several genes, including previously reported tumor sup-
pressors in lymphoma such asTNFAIP3,EPHA7, andPRDM1 (14,15, 35).
SESTRIN1 is rarely focally deleted and could thus be missed when
considering genomic data alone. Nonetheless, through complementary
functional analyses using a chimeric mouse model of lymphoma, we
could demonstrate the importance of SESTRIN1 in FL development.
In addition to chromosomal loss, SESTRIN1 is epigenetically
silenced by the lymphoma-specific mutant EZH2Y641X, resulting in
mTORC1 activation in lymphoma. SESTRIN1 is not a target of mu-
tations, in contrast to the RRAGC, which is mutated in 7% of FLs
(11). Mutations in EZH2 and RRAGC and loss of SESTRIN1 show
a mutually exclusive relationship, indicating that they are alternate
paths to maintain mTORC1 activity under conditions that would oth-
erwise shut down cell growth. The combined frequency of these le-
sions (47% of examined cases of FL and DLBCL) indicates that
maintaining active mTORC1 signaling is an important biological
requirement in a large group of lymphomas. There are functional
differences between SESTRIN1 and RRAGC. Although SESTRIN1
controls the Rag GTPases RAGA and RAG B in response to genotoxic
stress (19, 20), RRAGCencodes for theRAGCprotein that, togetherwith
RAG D, mediates nutrient-sensitive mTORC1 control (36). However,6 of 10
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cells. Data are shown as a bar graph cor-
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periment had two or three technical
replicates. (B) Immunoblot with the indi-
cated antibodies in OCI-LY19 and SU-DHL-5
lymphoma cells (EZH2WT/p53WT) and SU-DHL-10
and VAL cells (EZH2Y641X/p53WT) treated
withDXRor vehicle for 6 hours. (C) Analysis
of S6 and 4EBP1 phosphorylation in
EZH2Y641X-mutated lymphoma cell lines
SU-DHL-10 andSU-DHL-6 treated for 72hours
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(D) Immunoblot to assess S6 and 4EBP1
phosphorylation in SU-DHL-10 cells with
mutations in SESTRIN1 genomic locus
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for 72 hours). (E) Flow cytometry analysis to
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ration in lymphoma cells treated with the
EZH2 inhibitor (GSK126) or rapamycin with
or without SESTRIN1. (F) Quantification of
the methionine synthetic analog incorpo-
ration. Data are shown as a bar graph
corresponding to the mean ± SD. (G and
H) Tumor growth curves of xenografted
SU-DHL-10 expressing vector (G) or
CRISPR-SESTRIN1 (H), treated for 14 days
with vehicle or GSK126. The mean tumor
volumes ± SD are expressed in cubic milli-
meter. P values were calculated by two-
tailed t test. n.s., nonsignificant difference
(P > 0.05). (I) Tumor weight in animals xe-
nograftedwith SU-DHL-10 cells expressing
vector or single-guide RNA (sgRNA) target-
ing SESTRIN1 (CRISPR-SESTRIN1) and treated
with the EZH2 inhibitor (75 mg/kg ip) for
14 days. P value was calculated by paired
t test. Data are shown as single valueswith
mean ± SD. (J) Representative images of
immunohistochemistry and histopathol-
ogy analyses of xenografted tumors ex-
pressing vector or sgRNA targeting Sestrin1
(CRISPR-SESTRIN1) and stained for cleaved
caspase3, phospho-S6, and phospho-4EBP1.
Quantification was performed with ImageJ.
Scale bars, 200 mm. (K) Graphic representa-
tion of RapaLink-1 molecular structure and
the FAT (FRAP-ATM-TTRAP), FRB, and kinase
mTOR domains targeted by the inhibitor. (L) Percentage of viable cells in EZH2Y641X mutant and EZH2WT cells treated with the mTOR inhibitor (12.5 nM RapaLink-1) for 48 hours.
Each cell linewas analyzed in triplicate, and two-tailed t test was used to assess the significance of the difference in response between EZH2Y641Xmutant and EZH2WT cells. Data are
shown as a bar graph corresponding to the mean ± SD.(2017) 28 June 2017 7 of 10
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 mutual exclusivity between RRAGC and SESTRIN1 alterations indi-
cates that either lesion is sufficient to maintain mTORC1 in lympho-
ma cells.
The polycomb factor EZH2 is a target of activatingmutations in 7 to
20% of human FLs, promoting increase in H3K27me3 genome-wide
and thus targeting several genes. We showed that SESTRIN1 is an im-
portant EZH2Y641X target, and it may influence therapeutic response to
EZH2 inhibitors like GSK126. Our findings show that EZH2 controls
mTORC1 through SESTRIN1, and this epigenetic control can override
p53 and DNA damage–induced mTORC1 blockade. We further find
that SESTRIN1 reactivation and mTORC1 control are important
downstream effects of EZH2 gain-of-function mutations. This is
supported by the genetic relationship between these lesions and exper-
imental data showing that SESTRIN1 loss protects against EZH2 inhi-
bition.Althoughwe donot have direct clinical evidence and it is difficult
to test the efficacy of EZH2 inhibitors on primary FL samples because of
their limited ability to grow in vitro, these results suggest that SESTRIN1
deletions may predict reduced efficacy of EZH2 inhibitor treatment in
lymphoma.Conversely, our results reveal that EZH2-mediated epigenetic
down-regulation of SESTRIN1 increases the dependency of lymphomas
on mTORC1 and induces sensitivity to mTORC1 inhibitors in EZH2
mutant lymphomas. Together, our study establishes an epigenetic mech-
anism of mTORC1 control and suggests that SESTRIN1 status should
have an impact on the response to lymphoma therapeutics. by guest on July 3, 2017
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Study design
This study was designed to identify tumor suppressor genes in FL that
are targeted by chromosomal deletions and/or epigenetically silenced.
Initially, we analyzed array comparative genomic hybridization data
(aCGH) for 260 FL patients and used an shRNA screen in murine
pro–B cells (as a surrogate model) to identify genes that control B cell
proliferation. We confirmed the screen results in pro–B cells and in a
murine model of FL (vavP-Bcl2) (Figs. 1 and 2). We calculated the
minimum number of animals needed to observe significant differ-
ences in the survival curve by power analysis. In the second part of
the study (Figs. 3 and 4), we focused on epigenetic regulation. We ana-
lyzed expression data in FL and GC-DLBCL patient samples that were
EZH2WT or EZH2Y641X. We selected patients harboring EZH2Y641X
mutations; we excluded a cell line with UTX mutations and patients
harboring different mutations for EZH2. To confirm a direct effect of
mutated EZH2 onH3K27me3, we comparedH3K27me3 ChIP at the
gene-specific locus in mutant or wild-type EZH2 cells. To compare
different responses to the EZH2 inhibitor (GSK126), we used genet-
ically modified cells. Syngeneic cells were transplanted subcutaneously,
and tumor size was determined by direct measurement of the tumors.
We selected animals with similar tumor size and randomly assigned
them to untreated and treated groups. The number of replicates and
the statistical analyses are reported in the figure legends and below.
Statistical analysis
Significant differences in mRNA expression measured by RNA se-
quencing (fragments per kilobase of transcript per million) were
determined by Wilcoxon rank test. Differential expression analyses
on microarray data were performed using the Limma R package. Sig-
nificant differences in expressionmeasured by qPCRwere determined
by one- or two-tailed t test as reported in each figure legend. Statistical
significance of mutual exclusivity was determined by random permu-Oricchio et al., Sci. Transl. Med. 9, eaak9969 (2017) 28 June 2017tation tests (n = 1000). The bar graphs show the mean and SD or SEM
as indicated in the figure legends. The exact P values are reported in
each figure, and n.s. stands for non–statistically significant (P > 0.05).SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/9/396/eaak9969/DC1
Materials and Methods
Fig. S1. Genomic analysis of frequently altered regions in 260 FLs.
Fig. S2. Characterization of vavBcl2 lymphoma mouse model.
Fig. S3. Characterization of epigenetics and expression of SESTRIN1, SESTRIN2, and SESTRIN3 in
FL and DLBCL.
Fig. S4. Regulation of mTOR signaling by SESTRIN1 in lymphoma.
Table S1. Copy number analysis of 260 indolent FL samples.
Table S2. Quantification of homozygous and heterozygous deletions on Chr. 6q in 260 FL.
Table S3. Analysis of focal deletions on Chr. 6q.
Table S4. shRNA screen analysis.
Table S5. Sestrin1 expression in EZH2WT or EZH2Y641X GCB-DLBCL patient samples.
Table S6. Differential expression analysis of genes on Chr. 6q in EZH2WT or EZH2Y641X cell lines.
Table S7. Differential expression analysis of cell lines treated with the EZH2 inhibitor (GSK126)
or DMSO.
Table S8. List of lymphoma cell lines with relevant genomic lesions.
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and epigenetic status and also reported that mutations in EZH2 itself can sensitize cancer cells to additional
cancer types. The authors demonstrated that the effectiveness of targeting EZH2 depends on SESTRIN1 genetic 
a mechanistic connection between SESTRIN1 and EZH2, an epigenetic modifier that plays a role in multiple
The authors examined the mechanism by which the loss of SESTRIN1 contributes to tumorigenesis and identified 
 as a likely tumor suppressor.SESTRIN1 examined the genes on this chromosome and identified et al.Oricchio 
specific targeted therapy is available. Knowing that deletions of chromosome 6q are common in this tumor type, 
Follicular lymphoma is a relatively common and difficult-to-treat hematologic malignancy, for which no
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